Print Clear

Prior Authorization Request Administrative Information

Member Information

Last name _____ First name _____ MI _____

Member ID _____ Date of birth _____

Sex assigned at birth ☐ Female ☐ Male ☐ "X" or Intersex

Current gender ☐ Female ☐ Male ☐ Transgender male ☐ Transgender female ☐ Other _____

Place of residence ☐ Home ☐ Nursing facility ☐ Other _____

Race/ethnicity _____ Preferred spoken language _____ Preferred written language _____

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan Contact Information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan
☐ **MassHealth Drug Utilization Review Program** Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
☐ **Fallon Health** Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
☐ **Health New England** Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
☐ **Mass General Brigham Health Plan** Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555
☐ **Tufts Health Plan** Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
☐ **WellSense Health Plan** Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

over

Immune Globulin
Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Medication information

Medication requested

☐ Asceniv	☐ Gamastan S/D	☐ Gamunex-C	☐ Privigen
☐ Bivigam	☐ Gammagard	☐ Hizentra	☐ Xembify
☐ Cutaquig	☐ Gammagard S/D	☐ Hyqvia	
☐ Cuvitru	☐ Gammaked	☐ Octagam	
☐ Flebogamma	☐ Gammaplex	☐ Panzyga	

Dose of medication requested _____ mg per kg = _____

Frequency and duration of medication requested _____

Please specify dosing schedule. ☐ Scheduled ☐ Intermittent

Member's current actual body weight (ABW) _____ Date _____

Member's current height _____ Date _____

Member's current Body Mass Index (BMI) _____ Date _____

For initiation of intravenous immune globulin (IVIG), if a member's BMI is ≥ 30 kg/m^2 or ABW is > 120% of ideal body weight (IBW), dosing calculated using adjusted body weight has been demonstrated to have similar clinical effect as using ABW. MassHealth suggests the use of this dosing strategy to promote cost effective care. This is not meant to replace clinical decision making when initiating medication therapy. Please complete the below question.

If member meets the criteria noted above (BMI ≥ 30 kg/m^2 or ABW > 120% of IBW), is the member a candidate for adjusted body weight dosing? If criteria are not applicable, this may be left blank.

☐ Yes. MassHealth to calculate total dose based on adjusted body weight* (may round dose to vial size).

☐ No. Please explain why adjusted body weight* dosing is not appropriate for this member. _____

_____

** Adjusted Body Weight = IBW + 0.4 (ABW - IBW)*

Please indicate billing preference. ☐ Pharmacy ☐ Prescriber in-office ☐ Hospital outpatient

If applicable, please also complete section for professionally administered medications at end of form.

Drug NDC (if known) or service code _____

Indication or ICD-10 code, if applicable _____

Is the member stabilized on the requested medication?

☐ Yes. Please provide start date. _____ ☐ No

Section I. Please specify the indication for all requests except for a diagnosis of dermatomyositis (DM). For Asceniv requests, please also complete Section III as appropriate.

☐ Primary immunodeficiency disorders (PID)

Please attach laboratory documentation supporting diagnosis.

Provide date and results of most recent serum immunoglobulin levels (including laboratory reference ranges).

☐ Immune thrombocytopenia (ITP)

Provide date and results of most recent platelet count (including laboratory reference ranges).

Does the member have clinically significant bleeding? ☐ Yes. Please describe below. ☐ No

Does the member have a history of or risk of significant bleeding? ☐ Yes. Please describe below. ☐ No

Does the member have a medical necessity to raise platelet count within 12 to 24 hours?

☐ Yes. Please describe below. ☐ No

☐ Kawasaki disease (mucocutaneous lymph node syndrome)

Provide date of onset.

Does the member have an unexplained persistent fever? ☐ Yes ☐ No

Does the member have evidence of aneurysm? ☐ Yes ☐ No

Does the member exhibit signs of persistent inflammation? ☐ Yes ☐ No

☐ B-cell chronic lymphocytic leukemia (CLL)

☐ Chronic inflammatory demyelinating polyneuropathy (CIDP)

☐ Multifocal motor neuropathy (MMN)

☐ Other

Please describe the medical necessity for the use of immune globulin including previous trials and outcomes.

Section II. Please complete for treatment of dermatomyositis (DM). For Asceniv requests, please also complete Section III as appropriate.

1. Has the member had a trial with one systemic corticosteroid?

   ☐ Yes. Please list the dates/duration of trials and outcomes.* Dates/duration of trial

   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

   Briefly describe details of adverse reaction, inadequate response, or other.

   ☐ No. Please explain if there is a contraindication.
2. Does the member have severe disease? ☐ Yes ☐ No
3. Has the member had a trial with one of the following: azathioprine, chloroquine, hydroxychloroquine, methotrexate, mycophenolate mofetil, or rituximab?

over

☐ Yes. Please list the drug names, dates/duration of trials and outcomes below.*

Drug name Dates/duration of trial

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

☐ No. Please explain if there is a contraindication to these trials.

Section III. Please also complete for requests for Asceniv. Please complete Section I or II above as appropriate.

Please provide clinical rationale for the use of this product instead of other available IVIG products.

Section IV. Please complete and provide documentation for exceptions to Step Therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? ☐ Yes ☐ No

   If yes, briefly describe details of contraindication, adverse reaction, or harm.

2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?

   ☐ Yes ☐ No

   If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.

3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?

   ☐ Yes ☐ No

   If yes, please provide details for the previous trial.

   Drug name Dates/duration of use

   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response

   Briefly describe details of adverse reaction or inadequate response.

4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?

   ☐ Yes. Please provide details.

   ☐ No

over

Prior Authorization Request Prescriber and Provider Information

Prescriber Information

Last name* First name* MI

NPI* Individual MH Provider ID

DEA No. Office Contact Name

Address City State Zip

Email address

Telephone No.* Fax No.*

** Required*

Please also complete for professionally administered medications, if applicable.

Start date End date

Servicing prescriber/facility name ☐ Same as prescribing provider

Servicing provider/facility address

Servicing provider NPI/tax ID No.

Name of billing provider

Billing provider NPI No.

Is this a request for recertification? ☐ Yes ☐ No

CPT code No. of visits J code No. of units

Prescribing provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature _____

Printed name of prescribing provider Date

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)